Salomé Biennier
Research Subjects
Research Interests
Salomé Biennier has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aurore Duquenoy
MaaT Pharma, 69007 Lyon, France
1 shared publication - Carole Schwintner
MaaT Pharma, 69007 Lyon, France
1 shared publication - Joël Doré
Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France
1 shared publication - Mathieu Fontaine
MaaT Pharma, 69007 Lyon, France
1 shared publication - Nathalie Corvaia
MaaT Pharma, 69007 Lyon, France
1 shared publication
Latest Publications
- Open Access
- 7 November 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (11) , 2256
Narrative Review: Advancing Dysbiosis Treatment in Onco-Hematology with Microbiome-Based Therapeutic Approach
This review explores the complex relationship between gut dysbiosis and hematological malignancies, focusing on graft-versus-host disease (GvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We discuss how alterations in microbial diversity and composition can influence disease development, progression, and treatment outcomes in blood cancers. The mechanisms by which the gut microbiota impacts these conditions are examined, including modulation of immune responses, production of metabolites, and effects on intestinal barrier function. Recent advances in microbiome-based therapies for treating and preventing GvHD are highlighted, with emphasis on full ecosystem standardized donor-derived products. Overall, this review underscores the growing importance of microbiome research in hematology–oncology and its potential to complement existing treatments and improve outcomes for thousands of patients worldwide.
- 7 November 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (11) , 2256
Open AccessNarrative Review: Advancing Dysbiosis Treatment in Onco-Hematology with Microbiome-Based Therapeutic Approach
This review explores the complex relationship between gut dysbiosis and hematological malignancies, focusing on graft-versus-host disease (GvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We discuss how alterations in microbial diversity and composition can influence disease development, progression, and treatment outcomes in blood cancers. The mechanisms by which the gut microbiota impacts these conditions are examined, including modulation of immune responses, production of metabolites, and effects on intestinal barrier function. Recent advances in microbiome-based therapies for treating and preventing GvHD are highlighted, with emphasis on full ecosystem standardized donor-derived products. Overall, this review underscores the growing importance of microbiome research in hematology–oncology and its potential to complement existing treatments and improve outcomes for thousands of patients worldwide.